



SYNTHESIS AND ANTI-EPILEPTIC ACTIVITY OF SOME NOVEL 3-(4-(4-(SUBSTITUTED 
BENZYLIDENEAMINO)-5-MERCAPTO-4-1,2,4-TRIAZOLE-3-YL)PHENYLIMINO)-1-
((DIMETHYL AMINO) METHYL)-5-FLUOROINDOLIN-2-ONE DERIVATIVES 
Original Article 
 
CHINNASAMY RAJARAM PRAKASHa,*, SUNDARARAJAN RAJAb, GOVIDARAJ SARAVANANc 
aDepartment of Medicinal Chemistry, DCRM Pharmacy College, Jawaharlal Nehru Technological University, Hyderabad, Andhra Pradesh, 
India, bDepartment of Pharmaceutical Chemistry, GITAM Institute of Pharmacy, GITAM University, Visakhapatnam, Andhra Pradesh, 
India, cMedicinal Chemistry Research Laboratory, Bapatla College of Pharmacy, Bapatla- 522 101, Andhra Pradesh, India. 
Email: crp2020@gmail.com 
Received: 13 Jul 2014 Revised and Accepted: 10 Aug 2014 
ABSTRACT 
Objective: Synthesis and anti-epileptic evaluation of some novel Schiff and Mannich bases of isatin derivatives. 
Methods: A series of novel 3-(4-(4-(substituted benzylideneamino)-5-mercapto-4-1,2,4-triazole-3-yl)phenylimino)-1-((dimethyl amino) methyl)-5-
fluoroindolin-2-one Schiff and Mannich base derivatives were synthesized by using various aromatic aldehydes with isatin derivatives. The 
chemical structures of all synthesized compounds were confirmed by IR, 1
Results: The results of anti-epileptic activity showed that some of the synthesized compounds were exhibited significant results.  
H-NMR, Mass spectra and elemental analysis. All the synthesized 
compounds were screened for its anti-epileptic activity by MES and scPTZ methods using Phenytoin and Ethosuximide as standards.  
Conclusion: This investigation identified the potent anti-epileptic agents and these molecules will be subjected to further studies in our laboratory. 
Keywords: Schiff bases, Mannich Bases, Isatin, Anti-epileptic Activity.  
 
INTRODUCTION 
Epilepsy is a chronic disorder of the brain that affects people in 
every country of the world. Epilepsy is characterized by paroxysmal, 
excessive and hypersynchronous discharges of large numbers of 
neurons. Epilepsy affects 1% of world’s population according to the 
epidemiological studies. The latest report of world health 
organization (WHO) says around 50 million people worldwide has 
epilepsy and nearly 80% of the people with epilepsy are found in 
developing regions. Current clinically available drugs produce 
satisfactory seizure control in 60–70% of patients [1]. Many studies 
have been reported that in India the prevalence rate of epilepsy 
varies from 1710 to 9780 cases per million populations. Despite the 
optimal use of available antiepileptic drugs (AEDs), many patients 
with epilepsy fail to experience seizure control and others 
experience the seizure control only at the expense of significant 
toxic effects. The limitations with conventional AEDs highlighted the 
need for developing newer agents for epilepsies [2]. Many studies 
revealed that isatin is a privileged lead molecule for scheming 
potential bioactive agents, and their derivatives constitute an 
important class of heterocyclic compounds and are shown to 
possess a broad spectrum of bioactivity. Schiff and Mannich bases of 
isatin derivatives play an important role in the medicinal chemistry 
because of their potential biological properties. They are reported to 
show a variety of pharmaceutical properties including 
anticonvulsant activity [3-11]. Similarly triazole is the core 
structural motif in a variety of different compounds in medicinal 
chemistry and has been reported to exhibit a broad range of 
biological properties, including anticonvulsant activity [12-16]. 
Heterocycles containing mercapto and amino groups are an 
attractive synthones for the construction of condensed heterocyclic 
rings. The amino and mercapto groups are the convenient 
nucleophiles to react with electrophiles. Prompted by these 
observations, it was contemplated to synthesize some isatin 
containing congeners of 1,2,4-triazole Schiff and Mannich bases with 
a view to explore their potency as better anticonvulsant agents.  
MATERIALS AND METHODS 
The chemicals and reagents used were obtained from various 
chemical units Qualigens, E. Merck India Ltd., CDH, and SD Fine 
Chem. These solvents used were of LR grade and purified before 
their use. All the melting points were taken in open glass capillary 
and are uncorrected. 1H-NMR spectra were taken on a Bruker ultra 
shield (400 MHz) NMR spectrometer in DMSO-d6 using 
tetramethylsilane [(CH3)4
General Procedure for the synthesis of title compounds (4a-4j) 
Si] as internal standard. Chemical shift (δ) 
are expressed in ppm. Mass spectra were obtained on a JEOL-SX-102 
instrument using electron impact ionization. All the IR spectra were 
recorded in KBr pellets on a Jasco FT-IR 410 spectrometer. 
Elemental analyses were performed on a Perkine Elmer model 240c 
analyzer and were within ±0.4% of the theoretical values. 
Preparation of 4-(5-Fluoro-2-oxoindolin-3-ylideneamino) 
benzoic acid (1) 
Equimolar quantities (0.1 mol) of 5-Fluoro isatin (16.5 g) and para 
amino benzoic acid (13.7 g) were dissolved in warm ethanol 
containing few ml of glacial acetic acid. The reaction mixture was 
refluxed for 2 h and set aside. The resultant product was collected 
and washed with dilute ethanol and recrystallized with ethanol 
chloroform mixture. 
Yield:68%; Mp:192-194; FT-IR (KBr): cm-1 3350 (NH); 3038 (Ar C–
H); 2500 (COOH); 1650 (C=N); 1710 (C=O, isatin); 1H NMR (400 
MHz, δ ppm): 6.78–7.64 (m, 7H, Ar-CH); 8.20 (s, 1H, -NH); 12.10 (s, 
1H, COOH); MS (EI) m/z: 284 [M+]; Anal. Calcd for C15H9FN2O3
Preparation of 4-(1-((dimethylamino)methyl)-5-fluoro-2-
oxoindolin-3-ylideneamino) benzoic acid (2) 
: C, 
63.38; H, 3.19; N, 9.86;. Found: C, 63.46; H, 3.18; N, 9.84. 
To the solution of 4-(5-Fluoro-2-oxoindolin-3-
ylideneamino)benzoic acid (1) (0.04 mol) in 95% absolute 
ethanol (100 mL), aqueous formaldehyde 37% (1.0 mL) was 
added. Then dimethylamine (0.04 mol) added slowly to the 
above solution under stirring. After the addition was over, the 
entire reaction mixture was stirred at room temperature for 3 h, 
and then kept aside for 48 h in refrigerator to form crystals. 
Finally the products in the form of crystals were separated by 
filtration, and vacuum dried. Desired compounds were finally 
recrystallized with ethanol to obtain pure product.  
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Yield:74%; Mp:198-200; FT-IR (KBr): cm-1 3072 (Ar C–H); 2550 
(COOH); 1668 (C=N); 1724 (C=O, isatin); 1H NMR (400 MHz, δ ppm): 
2.22 (s, 6H, -CH3); 4.20 (s, 2H, -CH2); 6.98–7.94 (m, 7H, Ar-CH); 
12.50 (s, 1H, COOH); MS (EI) m/z: 341 [M+]; Anal. Calcd for 





An equimolar mixture of 4-(1-((dimethylamino)methyl)-5-fluoro-2-
oxoindolin-3-ylideneamino) benzoic acid (2) and 
thiocarbohydrazide were heated at 180°C for 2 hours. The mixture 
was cooled to room temperature. The crude was washed with dilute 
ethanol and dried. The synthesized compound was recrystallized 
from ethanol. 
Yield:55%; Mp:206-208; FT-IR (KBr): cm-1 3410 (-NH2); 3026 (Ar C–
H); 1626 (C=N); 1736 (C=O, isatin); 1H NMR (400 MHz, δ ppm): 2.22 
(s, 6H, -CH3); 4.20 (s, 2H, -CH2); 5.62 (s, 2H, -NH2); 6.98–7.94 (m, 
7H, Ar-CH); 10.50 (s, 1H, -SH); MS (EI) m/z: 411 [M+]; Anal. Calcd for 
C19H18FN7
Preparation of 3-(4-(4-(Substituted benzylideneamino)-5-
mercapto-4-1,2,4-triazole-3-yl) phenylimino)-1-((dimethyl 
amino)methyl)-5-fluoroindolin-2-one (4a-4j) 
OS: C, 55.46; H, 4.41; N, 23.83;. Found: C, 55.50; H, 4.42; N, 
23.86. 
Title compounds (4a-4j) was synthesized by adding 3-(4-(4-amino-5-
mercapto-4-1,2,4-triazol-3-yl)phenylimino)-1-(dimethylamino) methyl)-
5-fluoroindolin-2-one (3) (0.01 mol) in fraction with the well stirred 
mixture of different aromatic aldehydes (0.01 mol) in ethanol 50 mL and 
few mL of glacial acetic acid. Then this mixture was refluxed for 8 h and 
kept aside. The product that separated out was filtered, dried and 
recrystallized from ethanol. The method used for the preparation and 
isolation of the compounds gave materials of good purity, as evidenced 




FT-IR (KBr): cm-1 3010 (Ar C–H); 1730 (C=O, isatin); 1558 (CH=N); 
1H NMR (400 MHz, δ ppm): 2.42 (s, 6H, –CH3); 4.26 (s, 2H, –CH2); 
6.82–7.68 (m, 12H, Ar-CH); 8.60 (s, 1H, CH=N); 10.60 (s, 1H, -SH). MS 
(EI) m/z: 499 [M+]; Anal. Calcd for C26H22FN7OS: C, 65.21; H, 4.44; 
































































4f  = 3-NO2
4g = 4-Cl
4h = 2-Cl
4i  = 4-F
4j  = 4-Br
R
Scheme 1: Synthetic protocols of intermediates and title compounds  
Prakash et al. 




Table 1: Physicochemical characterization of compounds 4a-4j 
Compound R Mol. formula % yield Mp (°C) 
4a H C26H22FN7 58 OS 230-232 
4b 4-CH C3 27H24FN7 62 OS 248-250 
4c 4-OCH C3 27H24FN7O2 46 S 216-218 
4d 4-OH C26H22FN7O2 60 S 202-204 
4e 4-NO C2 26H21FN8O3 64 S 220-222 
4f 3-NO C2 26H21FN8O3 56 S 208-210 
4g 4-Cl C26H21ClFN7 72 OS 226-228 
4h 2-Cl C26H21ClFN7 58 OS 240-242 
4i 4-F C26H21F2N7 66 OS 210-212 





FT-IR (KBr): cm-1 3100 (Ar C–H); 1748 (C=O, isatin); 1528 
(CH=N); 1H NMR (400 MHz, δ ppm): 2.10 (s, 3H, Ar-CH3); 2.48 (s, 6H, 
–CH3); 4.30 (s, 2H, –CH2); 6.76–7.86 (m, 11H, Ar-CH); 8.50 (s, 1H, 





OS: C, 63.14; H, 4.71; N, 19.09. Found: C, 63.20; H, 4.73; N, 
19.11. 
FT-IR (KBr): cm-1 3076 (Ar C–H); 1722 (C=O, isatin); 1550 
(CH=N); 1H NMR (400 MHz, δ ppm): 2.38 (s, 6H, –CH3); 2.80 (s, 3H, 
Ar-OCH3); 4.25 (s, 2H, –CH2); 6.78–7.74 (m, 11H, Ar-CH); 8.50 (s, 1H, 





S: C, 61.23; H, 4.57; N, 18.51. Found: C, 61.32; H, 4.59; 
N, 18.46. 
FT-IR (KBr): cm-1 3458 (Ar-OH); 3088 (Ar C–H); 1714 (C=O, isatin); 
1526 (CH=N); 1H NMR (400 MHz, δ ppm): 2.34 (s, 6H, –CH3); 4.28 (s, 
2H, –CH2); 5.20 (s, 1H, Ar-OH); 6.72–7.84 (m, 11H, Ar-CH); 8.50 (s, 





S: C, 60.57; H, 4.30; N, 19.02. Found: C, 60.44; H, 4.32; 
N, 18.98. 
FT-IR (KBr): cm-1 3058 (Ar C–H); 1734 (C=O, is at in); 1524, 1352 
(NO2); 1568 (CH=N); 1H NMR (400 MHz, δ ppm): 2.38 (s, 6H, –CH3); 
4.34 (s, 2H, –CH2); 6.64–7.72 (m, 11H, Ar-CH); 8.60 (s, 1H, CH=N); 





S: C, 57.35; H, 3.89; N, 20.58. Found: C, 57.44; H, 3.87; 
N, 20.62. 
FT-IR (KBr): cm-1 3045 (Ar C–H); 1732 (C=O, is at in); 1530, 1348 
(NO2); 1572 (CH=N); 1H NMR (400 MHz, δ ppm): 2.42 (s, 6H, –CH3); 
4.26 (s, 2H, –CH2); 6.70–7.84 (m, 11H, Ar-CH); 8.56 (s, 1H, CH=N); 





S: C, 57.35; H, 3.89; N, 20.58. Found: C, 57.28; H, 3.88; 
N, 20.60. 
FT-IR (KBr): cm-1 3026 (Ar C–H); 1736 (C=O, isatin); 1558 (CH=N); 
788 (Ar-Cl); 1H NMR (400 MHz, δ ppm): 2.38 (s, 6H, –CH3); 4.20 (s, 
2H, –CH2); 6.50–7.62 (m, 11H, Ar-CH); 8.66 (s, 1H, CH=N); 10.62 (s, 





58.48; H, 3.96; Cl, 6.64; N, 18.36. Found: C, 58.56; H, 3.98; Cl, 6.62; N, 
18.40. 
FT-IR (KBr): cm-1 3052 (Ar C–H); 1700 (C=O, isatin); 1545 (CH=N); 
768 (Ar-Cl); 1H NMR (400 MHz, δ ppm): 2.30 (s, 6H, –CH3); 4.34 (s, 
2H, –CH2); 6.72–7.86 (m, 11H, Ar-CH); 8.50 (s, 1H, CH=N); 10.54 (s, 





58.48; H, 3.96; N, 18.36. Found: C, 58.54; H, 3.97; N, 18.38. 
FT-IR (KBr): cm-1 3066 (Ar C–H); 1722 (C=O, isatin); 1552 
(CH=N); 1H NMR (400 MHz, δ ppm): 2.32 (s, 6H, –CH3); 4.40 (s, 2H, –
CH2); 6.64–7.92 (m, 11H, Ar-CH); 8.60 (s, 1H, CH=N); 10.58 (s, 1H, -




OS: C, 60.34; 
H, 4.09; N, 18.94. Found: C, 60.28; H, 4.10; N, 18.98. 
FT-IR (KBr): cm-1 3064 (Ar C–H); 1698 (C=O, isatin); 1542 
(CH=N); 1H NMR (400 MHz, δ ppm): 2.42 (s, 6H, –CH3); 4.46 (s, 2H, –
CH2); 6.72–7.88 (m, 11H, Ar-CH); 8.54 (s, 1H, CH=N); 10.53 (s, 1H, -
SH). MS (EI) m/z: 579 [M+2]; Anal. Calcd for C26H21BrFN7
Pharmacology 
OS: C, 
53.98; H, 3.66; N, 16.95. Found: C, 54.06; H, 3.68; N, 16.98. 
Antiepileptic activity 
All the synthesized compounds were evaluated for their 
antiepileptic effects using male albino mice (Swiss, 18-25 g) and rat 
(Wistar 100-150 g). The primary qualitative evaluations were 
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performed in mice involved two epilepsy tests (MES: Maximal 
Electroshock Seizure test and ScPTZ: Subcutaneous 
pentylenetetrazole). Acute neurological toxicity induced by the 
compounds in mice was assessed through standardized rotorod test. 
In the initial screening, candidate compounds were screened for 
their antiepilepsy potential through MES and scPTZ models in mice 
at a dose level of 30, 100 and 300 mg/kg by intraperitoneal (i.p) 
route and the groups of mice are tested at different time points (i.e., 
0.5 and 4 h) post administration of the test candidate. It is generally 
acknowledged that the MES model, which uses an electrical 
stimulus, induces generalized tonic-clonic seizures. Through 
electrical induction, it is used to help recognize those compounds 
which prevent seizure spread. The scPTZ is a model where the 
myoclonic seizures induced by chemical induction. It helps in 
identifying those compounds that might act by increasing seizure 
threshold. 
The maximal electroshock test (MES) 
The MES is a model for generalized tonic-clonic seizures and 
provides a hint of a compound’s ability to stop seizure spread when 
all neuronal circuits in the brain are maximally active. These 
seizures are extremely reproducible and are electro physiologically 
reliable with human seizures. For the MES, a drop of anesthetic and 
electrolyte solution (tetracaine hydrochloride (0.5%) in saline 
(0.9%)) was applied to the eyes of individual animal before to 
placement of the corneal electrodes. The electrical stimulus in the 
MES test was 50 milli Ampere, 60 Hz, for mice and 150 milli Ampere, 
60 Hz, for rats delivered for 0.2 seconds by an apparatus similar to 
that initially described by Woodbury and Davenport. Abolition of the 
hindleg tonic extensor component of the seizure was used as the 
endpoint. Mice are initially tested with different doses of 30, 100 and 
300 mg/kg of test compound given by i.p. injection at various 
intervals while rats are initially screened at a fixed dose of 30 mg/kg 
given by oral route. 
The subcutaneous pentylenetetrazole seizure test (scPTZ) 
Subcutaneous injection of the convulsant Pentylenetetrazole 
produces clonic seizures in laboratory animals. The scPTZ test 
detects the ability of test compounds to raise the seizure threshold 
of an animal and thus protect it from exhibiting a clonic seizure. 
Animals are pretreated with various doses of the test compound 
given by i.p. injection. The dose of Pentylenetetrazole which induce 
convulsions in 97% of animals (CD97
Acute toxicity-minimal motor impairment 
: 85 mg/kg mice) is injected 
into a loose fold of skin in the midline of the neck. The animals are 
placed in isolation cages to minimize stress and observed for the 
next 30 min for the presence or absence of a seizure. An episode of 
clonic spasms, approximately 3-5 seconds, of the fore and/or 
hindlimbs, jaws, or vibrissae is taken as the endpoint. Animals which 
do not meet this criterion are considered protected. 
To assess a compound’s undesirable side effects (toxicity), animals 
are monitored for overt signs of impaired neurological or muscular 
function. In mice, the rotorod procedure is used to disclose minimal 
muscular (MMI) or neurological impairment (MNI). When a mouse 
is placed on a rod that rotates at a speed of 6 rpm, the animal can 
maintain its equilibrium for long periods of time. The animal is 
considered toxic if it falls off this rotating rod three times during a 1 
min period. In addition to MMI, animals may exhibit a circular or 
zigzag gait, abnormal body posture and spread of the legs, tremors, 
hyperactivity, lack of exploratory behavior, somnolence, stupor, 
catalepsy, loss of placing response and changes in muscle tone. 
RESULTS AND DISCUSSION 
Chemistry 
The structures of the synthesized compounds were confirmed by 
elemental analyses and spectral (IR, 1H-NMR, and Mass) data. The 
formation of Schiff base in compound 1 is confirmed by the presence 
strong stretching vibration in its IR spectrum at 1620 cm-1. The 
formation of compound 2 was confirmed by the appearance of 
strong singlet at δ 2.22 for six protons in its 1H-NMR spectra which 
might be assigned to two CH3 group connected to the isatin through 
Mannich reaction. The formation of compound 3 was confirmed by 
the appearance of strong stretching vibration at 3340 due to the 
presence of primary amino group in triazole ring. The formation of 
compound 3 is also evidenced by its 1H-NMR spectrum showed a 
singlet at δ 10.50 ppm due to presence of SH group proton. The 
presence of CH=N stretching vibration at 1564 cm-1 in IR spectrum 
and a singlet for a proton attached to the imine carbon at δ 8.60 ppm 
in 1
For the identification of antiepileptic a ctivity in mice, test 
compounds were administered i.p. and challenged by MES and 
scPTZ. Compounds found to be active in these seizure challenges are 
generally regarded to be significantly useful candidates in treatment 
of partial, generalized and even absence seizures. The data regarding 
the antiepileptic screening of all the compounds are reported in 
table 2 and graphically represented in figure 1. 
H-NMR confirms the formation of 4a. Further mass spectrum 
confirmed their purity and molecular weight. 
Antiepileptic activity 
 
Table 2: Antiepileptic activity and neurotoxicity of compounds 4a-4j administered intraperitoneally to mice 
Compound MESa scPTZ screening b NT screening c screening 
0.5 h 4.0 hd 0.5 hd 4.0 hd 0.5 hd 4.0 hd d 
4a 300 300 - - ND ND 
4b - 300 - - ND ND 
4c - 300 - - ND ND 
4d 300 300 300 300 ND ND 
4e 100 300 100 300 ND ND 
4f - 300 - - ND ND 
4g 30 30 100 300 - - 
4h 100 300 - - ND ND 
4i 30 100 100 300 - - 
4j 30 100 100 300 100 300 
Phenytoin 30 e 30 - - 100 100 
Ethosuximide - f - 100 300 - - 
a Maximal electroshock test (administered intraperitoneally to mice at doses ranging from 30 to 300 mg/kg)., b Subcutaneous pentylenetetrazole 
test (administered intraperitoneally to mice at doses ranging from 30 to 300 mg/kg)., c Neurotoxicity (administered intraperitoneally to mice at 
doses ranging from 30 to 300 mg/kg)., d Time of test after drug administration., eReference drug, data for phenytoin ref [17]. , f
 
 Reference drug, data 
for ethosuximide ref [18]. , The sign – (mdash) represents an absence of activity at maximum dose administered (300 mg/kg). ND - Not determined 
In the MES investigation, three compounds 4g, 4i and 4j were found 
to be significantly active as they showed protection at the lowest 
dose of 30 mg/kg after 0.5 h. These compounds continued to show 
the activity after 4.0 h but at higher doses (100 mg/kg) except 4g, 
which continued the activity at same 30 mg/kg indicating the rapid 
onset as well as long duration of action of these compounds. The 
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hopeful nature of the compounds may be attributed due to the 
substitutions at the hydrophobic domain. These compounds had 
electron withdrawing groups at the para position of the hydrophobic 
aryl ring. In general it was observed that the para substituted 
derivatives were more active than the other derivatives. This may be 
because of the fact that the para substituted derivatives are better 
binds preferentially to the sodium channel. Compounds that showed 
protection at 100 mg/kg after 0.5 h were 4e, and 4h indicating the 
ability of these compounds to protect from seizures at relatively 
lower dose. These compounds were also active after 4.0 h at 300 
mg/kg dose. The higher dose required for longer duration of activity 
may be because of the high lipophilicity of the compounds as it 
results into bidirectional movements of the compounds through the 
blood-brain barrier. 
In the chemo shock investigation, most of the compounds showed 
moderate antiepileptic activity. Compounds that revealed protection 
in the scPTZ test, indicative the ability of substance to increasing 
seizure threshold, at a dose of 100 mg/kg after 0.5 h included 4e, 4g, 
4i and 4j. It was comparable to results obtained for ethosuximide 
which is recognized as reference antiepileptic for this screen. Other 
compounds that showed considerable antiepileptic activity were 4d 
at 300 mg/kg either after 0.5 h or 4.0 h. It was observed that in this 
method, the most active compounds have substitution at the para 
position of the distal aryl ring by electron releasing group resulted in 
increased antiepileptic activity. 
Neurotoxicity screen 
The results obtained showed that most of the candidate compounds 
exhibited neurotoxicity at doses higher than widely prescribed 
drugs Phenytoin or Carbamazepine. But while evaluating an 
antiepileptic compounds, separation between antiepileptic and 
neurotoxic dose is desirable. All the compounds evaluated for its 
neurotoxicity study except 4a-4f and 4h, due to its poor response in 
antiepileptic activity. In neurotoxic study only compound 4j were 
found to be neurotoxic at 100 mg/kg at 0.5 h and 300 mg/kg at 4 h, 
while the compounds 4g and 4i were not found to be neurotoxic at 
maximum administered dose.  
Antiepileptic activity of selected compounds on rats by oral 
administration  
A valuable property of candidate antiepilepsy is its ability to inhibit 
epilepsy when given by the oral route. This screen discloses the time 
of onset, the approximate time of peak effect (TPE) and the duration 
of antiepileptic activity or neurotoxicity. From the initial screen we 
identified three compounds that were further evaluated for oral 
availability using the MES acute seizure model and neurotoxicity in 
rats at a dose of 30 mg/kg. The compound includes 4g, 4i and 4j. 
The results obtained are presented in table 3 and graphically 
represented in figure 2. 
As can be seen from these data, the most active compounds are 4g 
which protected 100% (4/4) of rats at time points 1 h, 75% (3/4) at 
0.5 h, 2 h and 4 h. 25% (1/4) at 0.25 h. This molecule was more 
active and showed longer duration of satisfactory action. The other 
compounds 4i were moderately effective in rat MES oral screen and 
protected 75% (3/4) of tested animals at the time point 2 h and 4 h 
and 50% (2/4) at 0.5 h and 1 h. 25% (1/4) at 0.25 h. The least active 
molecule in this study is 4j which protected maximum of 50% at 0.5 
h and 4 h. All derivatives tested were non-neurotoxic when given 
orally. The in vivo data in rats confirmed absorption of compounds 
from gastrointestinal tract and also their penetration to central 
nervous system. The inhibition of electrically induced seizures that 
is characteristic for Phenytoin and Phenytoin-like drugs may 
indicate the influence of compounds on voltage depended Na+ 
channels as the most plausible mechanism of antiepileptic action.
 
 
Fig. 1: Antiepileptic and neurotoxicity of compounds 4a-4j in mice 
 
 
Fig. 2: Antiepileptic and toxicity of compounds 4g. 4i and 4j in rats
 
Table 3: Antiepileptic activity and toxicity of compounds 4g, 4i, and 4j administered orally (30 mg/kg) to rats 
Compound MES TOXa b 
0.25 h 0.5 hc 1 hc 2 hc 4 hc c 
4g 1/4 3/4 4/4 3/4 3/4 0/4 (-)d 
4i 1/4 2/4 2/4 3/4 3/4 0/4 (-)
4j 
d 
0/4 2/4 1/4 1/4 2/4 0/4 (-)
Phenytoin
d 
1/4 e 4/4 3/4 3/4 3/4 0/4 (-)d 
a Maximal electroshock test (dose of 30 mg/kg was administrated. The data indicate: number of rats protected/number of rats tested)., b 
Neurotoxicity (number of rats protected/number of rats tested), c Time after drug administration., d (-) No neurotoxicity at dose tested, e
 
 Reference 
drug, data for phenytoin ref.(19) 
Structure Activity Relationships (SAR) analysis 
On correlating the structures of the sample candidate with their 
biological activity, it has been observed that, for the 10 novel 
derivatives 4a-4j, three compounds (4g, 4i and 4j) has selectivity 
towards MES (at 30 mg/kg) and the same compounds in addition 
with 4e had scPTZ activity (at 100 mg/kg).  
 
All the above mentioned four compounds were all p-substituted. The 
position of the substituted group on the phenyl ring appeared to 
greatly influence the antiepileptic activity; the p-chloro derivative 4g 
exhibited higher antiepileptic activity than the o-chloro derivative 4h. 
At the same p-position, the compound with fluorine substitution 4i 
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exhibited higher antiepileptic activity than the compound with nitro 
substitution 4e. Moreover, p-OCH3 and p-CH3
1. Perucen E. The new generation of antiepileptic drugs:advantages 
and disadvantages. Br J Clin Pharmacol 1996;42:531-43. 
 substituted compounds 
4c and 4b had no activity at all. However, the unsubstituted phenyl 4a 
and the phenyl ring substituted by p-OH 4d compounds exhibit 
slighter antiepileptic activity. In this series, generally compounds with 
electron withdrawing groups exhibited significant antiepileptic 
activity in comparison to electron donating group. 
CONCLUSION 
We have designed (Based on the pharmacophore model) and 
synthesized the title compounds while remembering the fact that a 
majority of clinically active antiepileptics possess a nitrogen hetero 
atomic system with one or two phenyl rings, at least one carbonyl 
group in their structure and presence of hydrogen donor/Acceptor 
unit. The structure of the title compounds 4a-4j satisfied all the 
pharmacophoric structural requirements. All the ten compounds are 
screened for their antiepileptic activity by MES and scPTZ model 
along with its neurotoxicity. Among the screened compounds, 4g, 4i, 
and 4j were found significant in MES screening, while the same 
compounds in addition with 4e showed noteworthy antiepileptic 
activity in scPTZ model. Compounds 4g, 4i and 4j were selected for 
oral administration in rats at 30 mg/kg dose. Compounds 4g and 4i 
exhibited comparable antiepileptic activity in oral dose compared 
with phenytoin. The most active was 3-(4-(4-(4-
Chlorobenzylideneamino)-5-mercapto-4-1,2,4-triazole-3-yl) phenyl 
imino)-1-((dimethyl amino) methyl)-5-fluoroindolin-2-one (4g) that 
revealed protection in the electrically induced seizures at a dose of 
30 mg/kg at 0.5 h and 4 h after i.p. administration respectively. This 
molecule provided also protection in the scPTZ at a dose of 100 
mg/kg in 0.5 h and 300 mg/kg at 4.0 h time intervals. Compound 4g 
emerged out as the lead molecule with a wide spectrum of 
antiepileptic activity without any neurotoxicity. 
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